Clinical effect of Voriconazole+Itraconazole in the treatment of secondary fungal infections of hematological malignancies
JIANG Peng-fei1 LIU Jia2▲
1.Department of Oncology and Hematology, Jingmen Traditional Chinese Medicine Hospital, Hubei Province, Jingmen 448000, China；
2.Department of Rehabilitation, Jingmen Traditional Chinese Medicine Hospital, Hubei Province, Jingmen 448000, China
Abstract：Objective To analyze the difference of efficacy of Voriconazole+Itraconazole and Voriconazole alone in the treatment of patients with secondary fungal infections of hematological malignancies.Methods A total of 120 patients with secondary fungal infections of hematological malignancies treated in our hospital from June 2017 to June 2018 were selected as the research objects.According to the sequence of admission, the patients were divided into observation group and reference group, with 60 cases in each group.Patients in the observation group were treated with Voriconazole+Itraconazole, and patients in the reference group were treated with Voriconazole alone.The therapeutic effect, the incidence of adverse reactions, the levels of inflammatory factors (tumor necrosis factor α [TNF-α], interleukin-4 [IL-4], interleukin-10 [IL-10], interleukin-12 [IL-12]) before and after treatment, improvement time of clinical symptoms (fever, cough, sputum, nausea, septic shock, and respiratory failure) were compared between the two groups.Results The total effective rate of the observation group was higher than that of the control group, and the difference was statistically significant (P＜0.05).There was no significant difference in the total incidence of adverse reactions between the two groups (P＞0.05).Before treatment, there were no statistically significant differences in the contents of TNF-α, IL-12, IL-4 and IL-10 between the two groups (P＜0.05).After treatment, the levels of TNF-α, IL-12 in both groups were lower than those before treatment, and the levels of IL-4 and IL-10 were higher than those before treatment, with statistical differences (P＜0.05).After treatment, the levels of TNF-α and IL-12 in the observation group were lower than those in the control group, and the levels of IL-4 and IL-10 were higher than those in the control group, with statistical differences (P＜0.05).The improvement time of fever, cough, sputum, nausea, septic shock, and respiratory failure in the observation group was shorter than that in the control group, and the difference was statistically significant (P＜0.05).Conclusion The application of Voriconazole+Itraconazole in the treatment of patients with secondary fungal infections of hematological malignancies has definite clinical effects, and it can improve the clinical symptoms and inflammatory factor levels of patients as soon as possible, which is suitable for clinical application and promotion.
蒋鹏飞; 刘佳. 伏立康唑联合伊曲康唑治疗血液恶性肿瘤继发真菌感染的临床效果[J]. 中国当代医药, 2020, 27(11): 95-98.
JIANG Peng-fei; LIU Jia. Clinical effect of Voriconazole+Itraconazole in the treatment of secondary fungal infections of hematological malignancies. 中国当代医药, 2020, 27(11): 95-98.
京公网安备 11010502046607号